Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts

Neuro-Oncology

Volumn 2, Issue 2, 2000, Pages 103-113

  Geoerger, Birgit ^a   Tang, Cheng Bi ^a   Cesano, Alessandra ^c   Visonneau, Sophie ^c   Marwaha, Sunil ^b   Judy, Kevin D ^d   Sutton, Leslie N ^b   Santoli, Daniela ^c   Phillips, Peter C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b Department of Neurosurgery ^*  (United States)

^c WISTAR INSTITUTE   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; BRAIN TUMOR; CANCER TRANSPLANTATION; CARCINOMA; CAROTID ARTERY; CELL CULTURE; CELL STRAIN K 562; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG SCREENING; GLIOBLASTOMA; HUMAN; IMMUNOLOGY; INTRAARTERIAL DRUG ADMINISTRATION; INTRALESIONAL DRUG ADMINISTRATION; MEDULLOBLASTOMA; METHODOLOGY; NUDE RAT; PATHOLOGY; RADIATION EXPOSURE; RAT; SQUAMOUS CELL CARCINOMA; STEREOTAXIC SURGERY; TRANSPLANTATION;

ANIMALS; BRAIN NEOPLASMS; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CAROTID ARTERIES; CYTOTOXICITY, IMMUNOLOGIC; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRALESIONAL; K562 CELLS; MEDULLOBLASTOMA; NEOPLASM TRANSPLANTATION; RATS; RATS, NUDE; STEREOTAXIC TECHNIQUES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034172941     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1093/neuonc/2.2.103     Document Type: Article

References (32)

1. Blasberg, R.G., and Groothuis, D.R. (1986) Chemotherapy of brain tumors: Physiological and pharmacokinetic considerations. Semin. Oncol. 13, 70-82.
2. Brenan, M., and Parish, C.R. (1984) Intracellular fluorescent labelling of cells for analysis of lymphocyte migration. J. Immunol. Methods 74, 31-38.
3. Bullard, D.E., Bigner, S.H., and Bigner, D.D. (1985) Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Res. 45, 5240-5245.
4. Cesano, A., and Santoli, D. (1992a) Two unique human leukemic T-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity analysis and modulation of their lytic mechanisms. In Vitro Cell. Dev. Biol. 28A, 648-656.
5. Cesano, A., and Santoli, D. (1992b) Inducible expression of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and interferon-γ in two human cytotoxic leukemic T cell lines. In Vitro Cell. Dev. Biol. 28A, 657-662.
6. Cesano, A., Visonneau, S., Clark, S.C., and Santoli, D. (1993) Cellular and molecular mechanisms of activation of MHC non-restricted cytotoxic cells by IL-12. J. Immunol. 151, 2943-2957.
7. Cesano, A., Visonneau, S., Cioe, L., Clark, S.C., Rovera, G., and Santoli, D. (1994) Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J. Clin. Invest. 94, 1076-1084.
8. Cesano, A., Visonneau, S., and Santoli, D. (1995) Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line. Cancer Res. 55, 96-101.
9. Cesano, A., Visonneau, S., Jeglum, K.A., Owen, J., Wilkinson, K., Carner, K., Reese, L., and Santoli, D. (1996a) Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res. 56, 3021-3029.
10. Cesano, A., Visonneau, S., Pasquini, S., Rovera, G., and Santoli, D. (1996b) Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia. Cancer Res. 56, 4444-4452.
11. Cesano, A., Pierson, G., Visonneau, S., Migliaccio, A.R., and Santoli, D. (1996c) Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets. Blood 87, 393-403.
12. Cesano, A., Visonneau, S., Deaglio, S., Malavasi, F., and Santoli, D. (1998) Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells. J. Immunol. 160, 1106-1115.
13. Cesano, A., Visonneau, S., Tran, T., and Santoli, D. (1999a) Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor bearing mice. Int. J. Oncol. 14, 245-251.
14. Cesano, A., Wortman, J.A., Pourdehnad, M., Visonneau, S., Mozley, D., Bhatnagar, A., Alavi, A., and Santoli, D. (1999b) Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: Implications for adoptive cell therapy of cancer. Int. J. Oncol. 14, 233-244.
15. Croothius, D.R., Vriesendorp, F.J., Kupfer, B., Warnke, P.C., Lapin, G.D., Kuruvilla, A., Vick, N.A., Mikhael, M.A., and Patlak, C.S. (1991) Quantitative measurements of capillary transport in human brain tumors by computed tomography. Ann. Neurol. 30, 581-588.
16. Kornblith, P.L., and Walker, M. (1988) Chemotherapy for malignant gliomas. J. Neurosurg. 68, 1-17.
17. Kurpad, S.N., Friedman, H.S., Archer, G.E., McLendon, R.E., Petros, W.M., Fuchs, H.E., Guaspari, A., and Bigner, D.D. (1995) Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. Cancer Res. 55, 3803-3809.
18. 6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis (2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol. 39, 307-316.
19. O'Connor, R., Cesano, A., Lange, B., Finan, J., Nowell, P.C., Clark, S.C., Raimondi, S.C., Rovera, G., and Santoli, D. (1991) Growth factor requirements of childhood acute T-lymphoblastic leukemia: Correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood 77, 1534-1545.
20. Ozols, R.F., Masuda, H., and Hamilton, T.C. (1988) Mechanisms of cross-resistance between radiation and antineoplastic drugs. NCI Monogr. 5, 159-165.
21. Packer, R.J., Sutton, L.N., Goldwein, J.W., Perilongo, G., Bunin, G., Ryan, J., Cohen, B.H., D'Angio, G., Kramer, E.D., Zimmerman, R.A., Rorke, L.B., Evans, A.E., and Schul, L. (1991) Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. S. Neurosurg. 74, 433-440.
22. Phillips, P.C. (1991) Antineoplastic drug resistance in brain tumors. Neurol. Clin. 9. 383-404.
23. Rosenberg, S.A., Packard, B.S., Aebersold, P.N., Solomon, D., Topalian, S.L., Toy, S.T., Simon, P., Lotze, M.T., Yang, J.C., Seipp, C.A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J.P., and White, D.E. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. W. Engl. J. Med. 319, 1676-1680.
24. Schuster, J.M., Friedman, H.S., Archer, G.E., Fuchs, H.E., McLendon, R.E., Colvin, O.M., and Bigner, D.D. (1993) Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. Cancer Res. 53, 2338-2343.
25. Silverman, C.L., and Simpson, J.R. (1982) Cerebellar medulloblastoma: The importance of posterior fossa dose to survival and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys. 8, 1869-1876.
26. Theron, J., Villemure, J.G., Worthington, C., and Tyler, J.L. (1986) Superselective intracerebral chemotherapy of malignant tumours with BCNU: Neuroradiological considerations. Neuroradiology 28, 118-125.
27. Vick, N.A., Khandekar, J.D., and Bigner, D.D. (1977) Chemotherapy of brain tumors: The "blood-brain barrier" is not a factor. Arch. Neurol. 34, 523-526.
28. Visonneau, S., Cesano, A., Tran, T., Jeglum, K.A., and Santoli, D. (1997a) Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell TALL-104. Clin. Cancer Res. 3, 1789-1797.
29. Visonneau, S., Cesano, A., Torosian, M.H., and Santoli, D. (1997b) Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice. Clin. Cancer Res. 3, 1491-1500.
30. Visonneau, S., Cesano, A., Jeglum, K.A., and Santoli, D. (1999a) Adoptive therapy of canine mammary carcinoma with the human cytotoxic T cell line TALL-104. Oncol. Rep. 6, 1181-1188.
31. Visonneau, S., Cesano, A., Jeglum, K.A., and Santoli, D. (1999b) Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104. Clin. Cancer Res. 5, 1868-1875.
32. Whittington, R., and Faulds, D. (1993) Interleukin-2: A review of its pharmocological properties and therapeutic use in patients with cancer. Drugs 46, 446-514.